Welcome to our dedicated page for Atrion news (Ticker: ATRI), a resource for investors and traders seeking the latest updates and insights on Atrion stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Atrion's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Atrion's position in the market.
Atrion Corporation (Nasdaq - ATRI) reported revenues of $39.2 million for Q1 2021, down from $43.6 million in Q1 2020. Net income decreased to $7.7 million, with diluted earnings per share at $4.22, compared to $4.79 last year. Sequentially, revenues increased by $7.0 million, indicating recovery from previous declines. The company anticipates continued growth in elective surgeries as COVID-19 restrictions ease, despite modest second-quarter expectations. Gross margins fell from 46% to 42% due to increased employee costs during the pandemic, although operating income remained strong at 23% of sales.
Atrion Corporation (NASDAQ: ATRI) reported fourth quarter 2020 revenues of $32.2 million, down from $34.5 million in Q4 2019, with net income declining to $7.4 million from $8.1 million. Full year revenues fell 5% to $147.6 million compared to $155.1 million in 2019, resulting in net income of $32.1 million. Diluted earnings per share decreased to $17.44, down from $19.73. Although challenges remain due to Covid-19, the company anticipates mid-single digit revenue growth in 2021.
Atrion Corporation (NASDAQ: ATRI) announced a quarterly dividend of $1.75 per share on its common stock. This dividend is payable on March 31, 2021 to stockholders of record by the close of business on March 15, 2021. The company specializes in developing and manufacturing products primarily for medical applications, emphasizing its commitment to shareholder returns.
Atrion Corporation (ATRI) has declared a quarterly dividend of $1.75 per share, payable on December 15, 2020, to shareholders on record by December 1, 2020. This decision reflects the company's commitment to providing returns to its investors. Atrion is known for developing and manufacturing medical application products, underlining its role in the healthcare sector.
Atrion Corporation (NASDAQ: ATRI) reported third-quarter 2020 revenues of $33.8 million, a 13% decrease from $38.9 million in Q3 2019. Net income also fell to $7.2 million, down from $9.6 million, with diluted earnings per share at $3.95 compared to $5.15 the previous year. CEO David A. Battat noted a significant decline in surgical procedures due to COVID-19, which impacted results and is expected to continue in Q4. Despite these challenges, Atrion remains profitable and debt-free, holding $88.2 million in cash and investments.
Atrion Corporation (Nasdaq ATRI) announced an increase in its quarterly cash dividend from $1.55 per share to $1.75 per share. The Board of Directors declared this dividend, which is payable on September 30, 2020, to stockholders of record as of September 15, 2020. This enhancement reflects the company’s commitment to returning value to its shareholders while continuing to support its medical application products.
Atrion Corporation (NASDAQ: ATRI) reported second-quarter revenues of $38.0 million, down from $40.1 million in 2019, largely due to the pandemic's impact on elective surgeries. Net income decreased to $8.6 million from $9.7 million year-over-year, with diluted earnings per share at $4.68, down from $5.18. The company noted a 15% rise in the effective tax rate, affecting earnings. Despite challenges, Atrion maintained a diversified product portfolio and remains debt-free, with cash and investments totaling $87.5 million as of June 30, 2020.
Atrion Corporation (NASDAQ: ATRI) has declared a quarterly dividend of $1.55 per share on its common stock. This dividend is set to be paid on June 30, 2020, to stockholders who are on record as of the close of business on June 15, 2020. Atrion specializes in developing and manufacturing products primarily for medical applications, reinforcing its commitment to shareholder returns and stability.
Atrion Corporation (Nasdaq - ATRI) reported Q1 2020 revenues of $43.6 million, up 5% from $41.6 million in Q1 2019. However, net income decreased to $8.9 million from $9.4 million year-over-year, leading to diluted earnings per share of $4.79, down from $5.07. Despite challenges from the COVID-19 pandemic, the company increased revenue in fluid delivery products by 23%. Operating income rose 6%, but the outlook for 2020 is uncertain due to potential impacts from the pandemic and economic slowdown.